Link patented drug prices to per capita income: Panel #patientrights


SEEKING AFFORDABILITY

Ag overnment panel has proposed that prices of patented medicines be based on the country’s per capi ta income, a move that would substantially reduce prices of costly drugs made by global pharmaceutical firms. 

The proposal, which seeks the input of other government agencies as well as industry groups, could provoke the ire of Big Pharma, which has clashed with India over protec tion of intellectual property price regulations for generic drugs, and compulsory licens es for costly medicines.
A panel formed under the ministry of chemicals and fertilizers has recommended setting up a committee to negotiate with drugmakers to fix prices of costly drugs used to treat deadly diseases such as cancer, HIV and hepatitis.
The proposal is the latest in a series of measures taken by India to make medicines more affordable for the coun try’s 1.2 billion population.
“If we compare the per capita income with the prices of patented medicines in countries like Australia or France, prices in India are compara tively high and hence, they need to be regulated,” a senior ministry official told Reuters, declining to be identified because he was not authorized to speak with media.
Generic medicines account for more than 90% of India’s $13 billion pharmaceuticals market. US-based Abbott Laboratories has the largest share of the overall Indian drug market followed by Cipla.
The proposal, posted late on Monday on the ministry website, cites as an example the lung-cancer drug erlotinib HCL, sold by Roche Holding as Tarceva. In India, it costs Rs 35,450 for a month’s course of 100 mg tablets, equivalent to Rs 1,21,085 in France and Rs 1,21,650 in Australia.
Based on per capita gross national incomes, if the drug costs Rs 35,450 in India, its respective cost would be just Rs 11,643 in France and Rs 10,309 in Australia based on per capita income in the respective countries, the report said.
The Organization of Pharmaceutical Producers of India, which represents for eign drugmakers in India, did not reply to questions from Reuters.
“If stringent price regula tions are enforced then latest drugs will not be made availa ble in India,” said Ameet Hariani, managing partner at Hariani & Co, a Mumbaibased law firm that advises drugmakers and other companies. REUTERS

 

 

5 Comments (+add yours?)

  1. Trackback: Press Release- Campaign for Affordable Trastuzumab | kracktivist
  2. Trackback: #India- How Pharma Giants Use Litigation To Evade Fines | kracktivist
  3. Trackback: #India – Govt has no plans for National Health Bill #WTFnews | kracktivist
  4. cybershimla.Com
    Apr 09, 2013 @ 08:28:44

    I’m not that much of a internet reader to be honest
    but your blogs really nice, keep it up! I’ll go ahead and bookmark your site to come back in the future. Cheers

    Reply

  5. Trackback: Insight: In India, gift-giving drives drug makers’ marketing

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Archives

Kractivism-Gonaimate Videos

Protest to Arrest

Faking Democracy- Free Irom Sharmila Now

Faking Democracy- Repression Anti- Nuke activists

JAPA- MUSICAL ACTIVISM

Kamayaninumerouno – Youtube Channel

UID-UNIQUE ?

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 6,227 other followers

Top Rated

Blog Stats

  • 1,848,508 hits

Archives

February 2013
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728  
%d bloggers like this: